Objective: To carry out the research on the consistency evaluation of human papillomavirus(HPV) nucleic acid detection ability, evaluate the HPV nucleic acid detection proficiency of different domestic laboratories, so as to promote the mutual recognition of HPV nucleic acid detection results in domestic laboratories. Methods: HPV samples containing 14 different high-risk types (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66 and -68) and 2 low-risk types (HPV-6, -11) were prepared with both type specificity and quantitative accuracy. Then panel was sent to different laboratories in the form of blind samples for testing. The proficiency study results were evaluated by the method of total integral grading evaluation. Results: A total of 27 laboratories participated in this proficiency study, of which 22 laboratories’ test results were “satisfactory” and 5 laboratories’ test results were “unsatisfactory”, with a satisfaction rate of 81.5%. Conclusion: The capacity of HPV test in different laboratories varies greatly, and the detection ability of some laboratories is poor. It is recommended to analyze the causes, strengthen laboratory training and timely rectification from four aspects: personnel, equipment, kit and quality control, so as to improve their laboratory testing capabilities.
Tian Yabin
,
Jiang Deyun
,
Ren Shanshan
,
Liu Yadan
,
Li Lili
,
Xu Sihong
. Study on the Consistency Evaluation of Human Papillomavirus Nucleic Acid Detection Proficiency[J]. Chinese Pharmaceutical Affairs, 2025
, 39(4)
: 430
-438
.
DOI: 10.16153/j.1002-7777.2024-11-0017
[1] World Health Organization. Cervical Cancer[EB/OL].(2024-03-05) [2024-09-10]. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer.
[2] World Health Organization. Human Papillomaviru and Cervical Cancer[EB/OL]. (2024-03-05) [2024-09-10]. https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer.
[3] World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer As a Public Health Problem[R/OL].(2020-11-17)[2024-09-10].https://www.who.int/publications/i/item/9789240014107.
[4] World Health Organization. WHO Guideline for Screening and Treatment of Cervical Pre-cancer Lesions for Cervical Cancer Prevention, Second Edition.2021[R/OL]. (2021-07-06) [2024-09-10].https://www.who.int/publications/i/item/9789240030824.
[5] World Health Organization. Recommendations to Assure the Quality, Safety and Efficacy of Recombinant Human Papillomavirus Virus-like Particle Vaccines[R/OL].(2016-05-25) [2024-09-10].https://www.who.int/publications/m/item/recombinant-hpv-like-particle-vaccines-annex-4-trs-no-999.
[6] Poljak M, Oštrbenk Valenčak A, Gimpelj Domjanič G, et al.Commercially Available Molecular Tests for Human Papillomaviruses: a Global Overview[J]. Clin Microbiol Infect, 2020, 26(9): 1144-1150.
[7] 田亚宾,张春涛.人乳头状瘤病毒核酸分型检测试剂的研究进展[J].中华肿瘤杂志,2018,40(10):729-735.
[8] Eklund C, Zhou T, Dillner J.WHO Human Papillomavirus Laboratory Network. Global Proficiency Study of Human Papillomavirus Genotyping[J]. J Clin Microbiol, 2010, 48(11): 4147-55.
[9] Eklund C, Forslund O, Wallin KL, et al.Continuing Global Improvement in Human Papillomavirus DNA Genotyping Services: The 2013 and 2014 HPV LabNet International Proficiency Studies[J]. J Clin Virol, 2018, 101: 74-85.
[10] Eklund C, Mühr LSA, Lagheden C, et al.The 2019 HPV Labnet International Proficiency Study: Need of Global Human Papillomavirus Proficiency Testing[J]. J Clin Virol, 2021, 141: 104902.
[11] Arroyo Mühr LS, Eklund C, Lagheden C, et al.Improving Human Papillomavirus (HPV) Testing in the Cervical Cancer Elimination Era: The 2021 HPV LabNet International Proficiency Study[J]. J Clin Virol, 2022, 154: 105237.
[12] Yilmaz E, Eklund C, Lagheden C, et al.First International Proficiency Study on Human Papillomavirus Testing in Cervical Cancer Screening[J]. J Clin Virol, 2023, 167: 105581.
[13] 徐幸,王国飞,杨依绡,等. 2020~2022年度上海及其他省市临床实验室HPV6与HPV11型核酸检测室间质量评价结果分析[J]. 现代检验医学杂志,2024,39(1):179-185.
[14] 田亚宾,沈舒,周海卫,等. 第二代人乳头瘤病毒全基因组分型国家参考品的研制[J]. 中国医药生物技术,2023,18(5):458-461.
[15] 中国医师协会妇产科分会阴道镜及子宫颈病变专业委员会,《中华健康管理学杂志》编辑委员会. HPV DNA检测应用于健康体检人群子宫颈癌初筛的专家共识[J]. 中华健康管理学杂志,2022,16(10):665-672.
[16] 田亚宾,赵娟,沈舒,等.人乳头瘤病毒L1基因分型国家参考品的升级换代研制[J].分子诊断与治疗杂志,2024,119(7):1386-1389,1394.
[17] World Health Organization.Role of the Laboratory in HPV Surveillance and Vaccine Impact Monitoring/Human Papillomavirus Laboratory Manual[M].Geneva:World Health Organization, 2009: 7-13.
[18] 田亚宾,张春涛. 人乳头瘤病毒疫苗效力评价用核酸检测试剂的讨论及思考[J]. 中国生物制品学杂志,2020,33(3):346-351.
[19] Biological Agents.Volume 100 B. A Review of Human Carcinogens[M]. IARC Monogr Eval Carcinog Risks Hum, 2012, 100: 1-441.
[20] Tommasino M.The Human Papillomavirus Family and Its Role in Carcinogenesis[J]. Semin Cancer Biol, 2014, 26: 13-21.
[21] Burk RD, Harari A, Chen Z.Human Papillomavirus Genome Variants[J]. Virology, 2013, 445: 232-243.
[22] Silva LLD, Teles AM, Santos JMO, et al.Malignancy Associated with Low-Risk HPV6 and HPV11: A Systematic Review and Implications for Cancer Prevention[J]. Cancers (Basel), 2023, 15(16): 4068.
[23] ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in China[R/OL]. (2023-05-10)[2024-09-10]. https://www.hpvcentre.net.
[24] World Health Organization. WHO Technical Guidance and Specifications of Medical Devices for Screening and Treatment of Precancerous Lesions in the Prevention of Cervical Cancer[R/OL]. (2020-04-07) [2024-09-10]. https://www.who.int/publications/i/item/9789240002630.
[25] Ferguson M, Wilkinson DE, Zhou T.WHO Meeting on the Standardization of HPV Assays and the Role of the WHO HPV Laboratory Network in Supporting Vaccine Introduction Held on 24-25 January 2008, Geneva, Switzerland[J]. Vaccine, 2009, 27(3): 337-47.
[26] Yu Y, Hao J, Mohamed SB, et al.The Prevalence of Multiple or Single HPV Infection and Genotype Distribution in Healthy Chinese Women: A Systemic Review[J]. J Cancer Res Ther, 2024, 20(4): 1265-1273.
